Some molecular targeted therapies and immune checkpoint inhibitors are now being introduced for gastric cancer, and their molecular markers such as human epidermal growth factor receptor 2 (HER2) and MSI are good predictive markers. This evidence concerns the gene ERBB2 and gastric cancer.